Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ramucirumab + dacarbazine
- Development stage
- Unknown
- Lead developer
- Eli Lilly
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
Ramucirumab + dacarbazine is an investigational **combination therapy** consisting of the **monoclonal antibody ramucirumab** (targeting vascular endothelial growth factor receptor-2, VEGFR2) and the **alkylating agent dacarbazine (DTIC)**. Ramucirumab blocks VEGFR2–mediated angiogenesis, thereby inhibiting tumor vascularization, while dacarbazine causes DNA alkylation leading to cell death. This combination has been explored in phase 2 trials for the treatment of chemotherapy-naïve metastatic melanoma and is currently undergoing clinical evaluation for progressive well-differentiated metastatic pancreatic neuroendocrine tumors. Both agents are administered intravenously[2][3][4][5].
- Other names
- ramucirumab and dacarbazineramucirumab plus dacarbazine
02
Targets
VEGFR2 (Vascular endothelial growth factor receptor 2)
Beyond the preview
Go deeper on ramucirumab + dacarbazine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ramucirumab + dacarbazine.